Description
Product details
TRIGLICLAGLAZE 60 Gliclazide 60mg (SR) Pioglitazone 15mg and Metformin HCL 500mg(SR) TRIGLICLAGLAZE 60 is a combination medication designed to effectively manage type 2 diabetes mellitus by addressing multiple aspects of glucose regulation. It combines three key components: Gliclazide 60mg (SR), Pioglitazone 15mg, and Metformin HCI 500mg (SR), each contributing to improved blood sugar control through distinct mechanisms of action. Gliclazide 60mg (SR): Gliclazide is a sulfonylurea medication that stimulates the pancreas to release insulin. This insulin release helps lower blood sugar levels, especially after meals, by facilitating glucose uptake into cells. Pioglitazone 15mg: Pioglitazone belongs to the thiazolidinedione class and works by improving insulin sensitivity in peripheral tissues such as muscle and fat cells. Enhanced insulin sensitivity allows for better utilization of glucose, reducing insulin resistance and promoting more efficient blood sugar management. Metformin HCI 500mg (SR): Metformin is a biguanide medication that primarily works by reducing glucose production in the liver and increasing insulin sensitivity in muscle cells. It also improves glucose uptake by cells and reduces the absorption of glucose from the digestive tract. Key Benefits of TRIGLICLAGLAZE 60: Comprehensive Glucose Control: By combining Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), TRIGLICLAGLAZE 60 offers comprehensive control over blood sugar levels throughout the day. Stimulates Insulin Release: Gliclazide's action in stimulating insulin release from the pancreas helps manage postprandial (after-meal) glucose spikes, contributing to overall glucose control. Improves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in tissues, leading to better glucose uptake and utilization by cells. This helps reduce insulin resistance, a common feature of type 2 diabetes. Reduces Glucose Production: Metformin HCI lowers glucose production in the liver and improves insulin action in muscle cells, leading to lower fasting blood sugar levels and enhanced glucose utilization. Extended Release Formulation: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, providing consistent blood sugar control and minimizing the risk of hypoglycemia or hyperglycemia. Dosage and Administration: TRIGLICLAGLAZE 60 is typically taken orally once or twice daily, with meals to reduce gastrointestinal side effects. Dosage adjustments may be required based on blood sugar levels and individual response to treatment. Follow your healthcare provider's instructions. For further information: EMAIL: info@sterispharma.com / contact@sterispharma.com CALL/WHATSAPP: 7877551268, 7849827488 Order Now https://www.sterisonline.com/product/trigliclaglaze-60-134279
